Syrentis Clinical Research | Santa Ana, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Core Treatment Period:
LTE Treatment Period:
Key Exclusion Criteria:
Core Treatment Period:
LTE Treatment Period:
Note- Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
1,696 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal